A randomised, prospective, phase III clinical trial of primary bleomycin, ifosfamide and cisplatin (BIP) chemotherapy followed by radiotherapy versusradiotherapy alone in inoperable cancer of the cervix

Citation
J. Herod et al., A randomised, prospective, phase III clinical trial of primary bleomycin, ifosfamide and cisplatin (BIP) chemotherapy followed by radiotherapy versusradiotherapy alone in inoperable cancer of the cervix, ANN ONCOL, 11(9), 2000, pp. 1175-1181
Citations number
32
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Oncology,"Onconogenesis & Cancer Research
Journal title
ANNALS OF ONCOLOGY
ISSN journal
0923-7534 → ACNP
Volume
11
Issue
9
Year of publication
2000
Pages
1175 - 1181
Database
ISI
SICI code
0923-7534(200009)11:9<1175:ARPPIC>2.0.ZU;2-K
Abstract
Background: Phase II studies have shown primary (neo-adjuvant) chemotherapy with bleomycin, ifosfamide and cisplatin (BIP) is active against inoperabl e cervical cancer. We present here results of a randomised phase III multic entre trial comparing radical radiotherapy with neo-adjuvant BIP chemothera py followed by radical radiotherapy in patients with inoperable cervical ca ncer, designed to discover whether this combination might improve survival. Patients and methods: Patients with inoperable cervical carcinoma were rand omised to pelvic radiotherapy alone [RT] or two to three cycles of bleomyci n 30 units/24-hour infusion, ifosfamide 5 g/m(2)/24 hours, and cisplatin 50 mg/m(2)) chemotherapy followed by pelvic radiotherapy (BIP + RT). Randomis ation was stratified by stage and radiotherapy centre. Results: One hundred seventy-two eligible women were randomised into this t rial; eighty-six to RT and eighty-six to BIP + RT. A total of 190 cycles of chemotherapy were given. Median follow-up for the 47 patients still alive is 9 years with a minimum follow-up of 3 years. Complete or partial respons e occurred in 51 of 86 (59%) of those randomised to RT and 60 of 86 (69%) o f those randomised to BIP + RT. The difference between response rates does not reach statistical significance (chi(2) = 2.06, P = 0.15). Median surviv al is two years with an actuarial survival at five years of 32% (95% confid ence interval (95% CI): 25%-39%). There is no significant difference betwee n the treatment groups (chi(log-rank)(2) = 0.11, P = 0.74). Conclusions: This study does not show any survival benefit from the use of neo-adjuvant BIP chemotherapy in advanced cervical cancer.